🦊/Investors

BlueStone Venture Partners

Venture capitaloperating company · company profile

Tucson · Seed–Series B · 4 people tracked

Find your way into BlueStone Venture Partners

347 people in our graph share verified history with the BlueStone Venture Partners team — schools, employers, funds. One of them is your warm intro.

Sam Blackmanunlockedknows Mara Aspinall · together at Dana-Farber Cancer Institute (overlapped)
knows the team · via Tufts University
×5knows the team · via Harvard Business School
×3knows the team · via Allscripts
knows the team · via Dana-Farber Cancer Institute
knows the team · via Blue Cross Blue Shield of Massachusetts
Fox Verdict
Sign up to see your fit

Investment thesis

BlueStone Venture Partners invests in life sciences and information technology companies that operate outside the traditional venture capital hubs of the United States, with a particular focus on the desert Southwest. The firm believes the region holds overlooked opportunities supported by strong universities, unique research centers, and significant infrastructure, yet underserved by venture capital. Leveraging its management expertise, established deal pipelines, and relationships with industry-leading advisors and co-investors, the firm aims to identify promising companies and create value for its investors.

Source: firm website, verified Aug 3, 2026.

Stage
Seed–Series B
Check
$250K – $1M
HQ
Tucson, Arizona, US
Instruments
Equity
Founded
2018
Tracked investments
12

Team · 4 people

from the firm's website & public directories
Andrew More· Investor

What they invest in

from 12 of 12 portfolio companies

Biotech ×9Healthtech ×8Medical Devices ×5AI & Machine Learning ×3Deep Tech ×3Digital Health ×3Advanced Manufacturing ×1Hardware ×1

HQs:United States×8

Investments · 12 tracked

founders shown can be your intro path

By year:2023 · 22019 · 13 dated

Strateosstrateos.comin𝕏Apr 2019✓ verified

Strateos develops remote access laboratory software and automation platforms that enable scientists to design, execute, and analyze experiments through cloud-based robotics and control systems.

AI & Machine LearningBiotechDeep TechRoboticsSaaSMenlo Park, US

Chris Krueger(Executive Officer)inMark Fischer-Colbrie(Executive Officer, Director)inDavid Lynch, PhD(Chief Executive Officer)Marc Siladi(Chief Operating Officer)in

BoardJoshua Wolfe(Director)Armen Vidian(Director)in

Co-investorsDCVC (Data Collective)Lux CapitalThird Rock VenturesHarmonix FundSilicon BadiaAlly Bridge Group+3 more

Akadeum Life Sciencesakadeum.comin𝕏

Akadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products.

Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesAnn Arbor, US

Kalyan Handique(Executive Officer, Director)John Younger(Executive Officer, Director)inJames Militello(Executive Officer)

BoardJeffrey S. Williams(Director)Paul D'Amato(Director)inDan Kidle(Director)in

Co-investorsArboretum VenturesBeringeaBerkeley CatalystCANTILEVER INVESTORSeLab VenturesHemisphere Ventures LLC+7 more

CND Life Sciencescndlifesciences.comin

CND Life Sciences develops skin-based neurodiagnostic tests, including a test to detect abnormal alpha-synuclein in skin biopsies to help physicians diagnose Parkinson's disease and related synucleinopathies.

BiotechDigital HealthMedical DevicesScottsdale, US

Todd Levine(Executive Officer, Director)inRichard J. Morello(Executive Officer, Director)Peter Harris(Executive Officer, Director)inChristopher Gibbons(Director)

BoardJack Seaver(Director)Enrique Carrazana(Director)

Co-investorsTop Corner Capital

Elucidelucid.comin𝕏

Elucid develops artificial intelligence technology that analyzes CT images to identify hidden features of cardiovascular risk and guide personalized treatment of coronary artery disease.

AI & Machine LearningHealthtechMedical Devices

Co-investorsAngel Physicians FundAphelion CapitalIAG Capital Partners

Gtmedtechgtmedtech.comin𝕏

GT Medical Technologies develops GammaTile, an implantable radiation therapy device for treating operable brain tumors.

BiotechHealthtechMedical Devices

Co-investorsAccelmed PartnersEvidity Health CapitalFemHealth Ventures

NTx Biontxbio.comin

NTx Bio develops proprietary cell-free synthetic biology platforms for on-demand, decentralized biomanufacturing of mRNA and proteins.

BiotechDeep TechHardwareHealthtech

Co-investorsAnzu Partners

Paradigmdxparadigmdx.comin𝕏

Paradigm develops diagnostic tests for cancer, including assessments of hereditary risk, screening for the presence of cancer, and analysis of the genomic alterations in a patient's tumor to help guide treatment decisions.

BiotechDigital HealthHealthtech

Co-investorsNew Science Ventures

Preludedxpreludedx.comin𝕏

PreludeDx develops precision diagnostic tests for breast cancer to help physicians make informed treatment decisions and improve patient outcomes.

AI & Machine LearningBiotechHealthtechMedical DevicesNashville, US

Troy Bremer(Co-founder & Chief Scientific Officer)Daniel Forche(President & CEO)

Co-investorsFjord VenturesEvidity Health Capital

Pyx Healthpyxhealth.comin

Pyx Health provides a member engagement and activation solution for health plans, combining in-home fresh food delivery, human care teams, and a digital app to address non-medical drivers of health such as loneliness and food needs.

Digital HealthHealthtechWellness & FitnessTucson, US

Cynthia Jordan(Executive Officer, Director)

Co-investorsArizona Founders FundS2G InvestmentsFounders Fund

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Elucid BioimagingGT Medical TechnologiesNature's Toolbox

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has BlueStone Venture Partners made?
BlueStone Venture Partners has 12 tracked investments.
What stage does BlueStone Venture Partners invest at?
BlueStone Venture Partners invests at the Seed, Series A, Series B stages.
What is BlueStone Venture Partners's typical check size?
BlueStone Venture Partners typically writes checks of $250K – $1M.
What sectors does BlueStone Venture Partners focus on?
BlueStone Venture Partners focuses on Biotech, Digital Health, Enterprise Software, Healthtech, Medical Devices, New Materials.
Where is BlueStone Venture Partners located?
BlueStone Venture Partners is headquartered in Tucson, US.
Who does BlueStone Venture Partners co-invest with?
BlueStone Venture Partners most often shares deals with Evidity Health Capital, Anzu Partners, Arboretum Ventures, among 21 tracked co-investors.

Similar investors

Featured in lists